Headquartered in Louisville, KY with offices in Atlanta, GA and Rockville, MD, Emergint is a leading designer, developer, and integrator of systems that ingest, store, analyze, and disseminate complex data sets from disparate systems. The Company also provides full lifecycle systems development and an array of HIT consulting and support services. The Company’s founding vision and enduring core competency is to integrate large amounts of data from disparate systems to enable more meaningful use and application of the information. Emergint has proven past performance and technical and domain expertise in integrating and improving data, ensuring interoperability, and enhancing business intelligence. The Company supports priority programs, such as systems for bioterrorism surveillance and alerting, public health situational awareness, and measurement of healthcare effectiveness.
Emergint has an established footprint across various elements of HHS. It is one of the most active contractors at CDC with strategic relationships across multiple organizations, including the Office of Surveillance Epidemiology and Laboratory Services, Division of Health and Quality Promotion’s National Health Safety Network, and Office of Infectious Diseases. The Company has a deep organizational knowledge of CDC’s systems, operations, and requirements that afford it the ability to continue to deliver superior solutions, anticipate future requirements, and differentiate itself within that marketplace. Emergint is also well positioned to expand in adjacent customer communities including the National Institutes of Health (“NIH”), Environmental Protection Agency (“EPA”), Food and Drug Administration (“FDA”), and broader parts of HHS.
We believe this transaction demonstrates several key trends in the government technology M&A environment:
- Strong buyer appetite for companies well-positioned with mission-oriented customers, and oriented toward those market segments anticipating strong future growth, such as health IT, big data, and cyber and intelligence.
- Strategic buyers continue to target M&A opportunities that address strategic gaps or augment an existing presence with substantive depth in those priority areas.
- Given macro-economic and federal budget uncertainty, buyers seek targets with sustainable growth potential evidenced by actionable new business opportunities.
- Targets operating at the front-end of contracts (with significant backlog) that provide strong revenue visibility and organic growth potential are highly sought after.
KippsDeSanto & Co. is an investment bank focused on delivering exceptional M&A and financing transaction results for leading technology and defense companies. For more information on KippsDeSanto & Co., please visit www.kippsdesanto.com.
We welcome the opportunity to discuss how KippsDeSanto & Co. can help you achieve your strategic objectives.
KippsDeSanto & Co., member FINRA/SIPC, is not affiliated with other companies mentioned herein
CACI Completes Acquisition of Emergint Technologies, Inc.
Acquisition Expands Healthcare IT Solutions
ARLINGTON, Va.–(BUSINESS WIRE)– CACI International Inc. (NYSE: CACI) announced today that it has completed its transaction to acquire Emergint Technologies, Inc., a premier provider of emerging technology solutions focused on the data-driven needs of national health organizations. This acquisition builds on CACI’s healthcare IT capability and expands its presence in the growing healthcare IT market.
Founded in 1999, Emergint has 300 employees and is headquartered in Louisville, Kentucky. The company offers a wide range of healthcare-focused IT-related services that support the missions of federal and state customers. Its workforce has extensive experience providing health data integration and analysis solutions, management and IT consulting, and data and records management. Emergint has contract vehicles with key health-focused federal agencies, including the Centers for Disease Control and Prevention, National Institutes of Health, and U.S. Food and Drug Administration. Its 2012 revenue is expected to be approximately $42 million, and the acquisition is expected to be accretive to CACI’s earnings per share during its first 12 months.
John Mengucci, CACI Chief Operating Officer and President of U.S. Operations, said, “Emergint Technologies, Inc. is a wonderful addition to the CACI team, and their best-in-class capabilities in data analytics, integration, and analysis will greatly enhance our healthcare IT practice. Furthermore, we are positive that their commitment to integrity and client service will make them an excellent fit for our company and culture.”
According to Dan Allen, CACI President and Chief Executive Officer, “As the public health community continually focuses on increasing data information exchange and delivering improved results to enhance patient care, Emergint is a valuable addition to the CACI team. Their established relationships with federal health organizations will help us to further expand our footprint in the high-growth healthcare IT market.”
CACI provides information solutions and services in support of national security missions and government transformation for Intelligence, Defense, and Federal Civilian clients. A member of the Fortune 1000 Largest Companies and the Russell 2000 Index, CACI provides dynamic careers for approximately 14,900 employees working in over 120 offices worldwide. Visit www.caci.com.